Anaphylaxis in patients with congenital bleeding disorders and inhibitors-Reference-Cited by-同舟云学术

Anaphylaxis in patients with congenital bleeding disorders and inhibitors

Published:2009-06 Issue:4 Volume:20 Page:225-229
ISSN:0957-5235
Container-title:Blood Coagulation & Fibrinolysis
language:en
Short-container-title:

Author:

Franchini Massimo,Lippi Giuseppe,Montagnana Martina,Targher Giovanni,Zaffanello Marco,Salvagno Gian Luca,Rivolta Gianna Franca,Di Perna Caterina,Tagliaferri Annarita

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology,General Medicine

Reference43 articles.

1. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group;Lusher;N Engl J Med,1993

2. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs;Ehrenforth;Lancet,1992

3. Factor VIII alloantibodies in hemophilia;Jacquemin;Curr Opin Hematol,2004

4. Plasma-derived biological medicines used to promote haemostasis;Ofosu;Thromb Haemost,2008

5. Anaphylaxis in patients with hemophilia;Jadhav;Semin Thromb Hemost,2000

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review;Seminars in Thrombosis and Hemostasis;2024-06-27

2. Hematopoietic Stem Cell-Based Platelet-Targeted Gene Therapy for Hemophilia;Comprehensive Hematology and Stem Cell Research;2024

3. Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity;Blood Advances;2021-03-01

4. Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient;International Journal of Immunopathology and Pharmacology;2021-01

5. Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural);Haemophilia;2020-12-05